- Investing Ideas
- /
- Global Pure Equity Growth
Global Pure Equity Growth
Results
182
0 new
Companies that has zero debt on their balance sheet and is forecast to grow at an exponential rate in the future.
182 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
S1GE34 | US$56.70 | 6.7% | n/a | US$43.2b | US$56.74 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
ARGX N | €8,484.05 | 0% | n/a | €28.8b | €8,992.01 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
ARGXB | €486.10 | -1.2% | -1.2% | €28.8b | €515.20 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
1AEA | €360.00 | 0% | -26.2% | €28.8b | €381.55 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
A1RG34 | €119.64 | -0.3% | 19.0% | €28.8b | €126.80 | PS19.3x | E58.3% | n/a | Pharmaceuticals & Biotech | ||
ARGN.F | €525.60 | 0% | n/a | €28.4b | €557.07 | PS19.3x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
1AEA | €464.00 | -2.9% | -4.5% | €28.4b | €498.19 | PS19x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
ARGX | €529.06 | -1.6% | 2.9% | €28.4b | €568.04 | PS19x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
1AE | €467.70 | -2.9% | -4.1% | €28.4b | €502.16 | PS19x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
ARGX | €475.70 | -3.3% | -2.4% | €28.4b | €510.75 | PS19x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
0QW0 | €475.20 | -2.3% | -2.6% | €28.4b | €510.22 | PS19x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
ARGX | €473.20 | -3.5% | -2.7% | €28.4b | €508.07 | PS19x | E58.4% | n/a | Pharmaceuticals & Biotech | ||
DUOL | US$250.15 | 12.1% | 59.5% | US$10.6b | US$235.25 | PE164.4x | E41.6% | n/a | Consumer Services | ||
300502 | CN¥99.57 | 6.4% | 151.2% | CN¥70.6b | CN¥117.34 | PE55.8x | E42.9% | 0.2% | Tech | ||
300502 | CN¥99.57 | 6.4% | 151.2% | CN¥70.6b | CN¥117.34 | PE55.8x | E42.9% | 0.2% | Tech | ||
9992 | HK$49.25 | 4.0% | 103.9% | HK$65.2b | HK$53.85 | PE38.9x | E29.3% | 0.6% | Retail | ||
735 | HK$5.55 | 2.8% | 96.8% | HK$65.2b | HK$6.07 | PE38.8x | E29.3% | 0.6% | Retail | ||
9992 | HK$49.25 | 2.8% | 107.4% | HK$65.2b | HK$53.85 | PE38.9x | E29.3% | 0.6% | Retail | ||
9992 | HK$49.25 | 2.8% | 107.4% | HK$65.2b | HK$53.85 | PE38.9x | E29.3% | 0.6% | Retail | ||
I2TC34 | US$71.15 | 2.8% | n/a | US$8.0b | US$91.06 | PS14.1x | E64.4% | n/a | Pharmaceuticals & Biotech | ||
ITCI * | US$1,393.00 | 0% | n/a | US$7.9b | US$1,782.90 | PS14.1x | E64.4% | n/a | Pharmaceuticals & Biotech | ||
23I | US$68.00 | 2.3% | 34.7% | US$7.9b | US$87.03 | PS14.1x | E64.4% | n/a | Pharmaceuticals & Biotech |